Bob Hutchens, President and CEO
San Antonio, TX
StemBioSys is a privately-held biomedical company. Our technologies represent the next evolution in cell research and are branded to the research market under the CELLvo™ label. The centerpiece of these technologies is our broad range of CELLvo™ Matrices. These cell derived microenvironment allow a variety of cells to replicate more rapidly and express markers indicative of potency beyond that seen with traditional tissue culture substrates. The company also has several cell products isolated and expanded on our matrixies. Additionally, earlier this year, StemBioSys acquired CarTox. Together with CarTox, we are developing a novel approach for preclinical cardiac toxicity safety testing. Finally, recently the company and its scientific founder began development of a cell product that uses our proprietary matrix technology to treat Type 1 Diabetes.

By using this website you agree to accept our Privacy Policy and Terms & Conditions